Name: NexoBrid Active Ingredient: anacaulase-bcdb Indications: To remove eschar in adults with deep partial thickness or full thickness thermal burns Approval Date: 12/28/2022 Company: MediWound LTD Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761192s000lbl.pdf
Drug Name: Sunlenca Active Ingredient: lenacapavir Indications: To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations…
Drug Name: Lunsumio Active Ingredient: mosunetuzumab-axgb Indications: To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma Approval Date: 12/22/2022 Company: Genentech, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf
Drug Name: Krazati Active Ingredient: adagrasib Indications: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy…
Drug Name: Rezlidhia Active Ingredient: olutasidenib Indications: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation Approval Date: 12/1/2022 Company: Forma Therapeutics,…
Drug Name: Tzield Active Ingredient: teplizumab-mzwv Indications: To delay the onset of stage 3 type 1 diabetes Approval Date: 11/18/22 Company: Provention Bio, Inc. (a Sanofi company) Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf
Drug Name: Elahere Active Ingredient: mirvetuximab soravtansine-gynx Indications: To treat patients with recurrent ovarian cancer that is resistant to platinum therapy Approval Date: 11/14/2022 Company: ImmunoGen, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf
Drug Name: Tecvayli Active Ingredient: teclistamab-cqyv Indications: To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy Approval Date: 10/25/2022 Company:…
Drug Name: Imjudo Active Ingredient: tremelimumab Indications: To treat unresectable hepatocellular carcinoma Approval Date: 10/21/2022 Company: AstraZeneca Pharmaceuticals LP Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289s001lbl.pdf
A cheap malaria vaccine that can be produced on a massive scale has been recommended for use by the World Health Organization (WHO). The vaccine has been developed by the…